Tumor cell detection in peripheral blood and bone marrow

Current Opinion in Oncology

Volumn 18, Issue 1, 2006, Pages 48-56

  Zach, Otto ^a   Lutz, Dieter ^a  

^a ELISABETHINEN HOSPITAL   (Austria)

Author keywords

Circulating tumor cell; Disseminated tumor cell; Minimal residual disease

Indexed keywords

BLOOD; BLOOD ANALYSIS; BONE MARROW EXAMINATION; BREAST CANCER; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HUMAN; MARKER GENE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; SOLID TUMOR; TUMOR CELL; TUMOR DIAGNOSIS;

BONE MARROW; HUMANS; NEOPLASM CIRCULATING CELLS; NEOPLASM, RESIDUAL; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33646710101     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000198973.51615.fa     Document Type: Review

References (68)

1. Braun S, Naume Bh. Circulating and disseminated tumor cells. J Clin Oncol 2005; 23:1623-1626. This review refers to the results from several studies regarding the prognostic relevance of circulating and disseminated tumor cells.
2. Vlems FA, Ruers TJM, Punt CJA, et al. Relevance of disseminated tumour cells in blood and bone marrow of patients with solid epithelial tumours in perspective. Eur J Surg Oncol 2003; 29:289-302.
3. Slade MJ, Singh A, Smith BM, et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 2005; 114:94-100. Bone marrow samples from 51 non-metastatic breast cancer patients were tested at four time points for the presence of disseminated tumor cells. All of them were positive at least once, pointing to their persistence during therapy. The question remains unanswered whether these cells exhibit any oncogenic or metastatic potential.
4. Stathopoulos EN, Sanidas E, Kafousi M, et al. Detection of CK-19 mRNA positive cells in peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005; 16:240-246. The detection of circulating tumor cells did not correlate with sentinel or axillary lymph node involvement but they disappeared during treatment.
5. Yu JJ, Brennan M, Christos P, et al. Bone marrow micrometastases and adjuvant treatment of breast cancer. Breast J 2004; 10:181-185.
6. Zehentner BK, Persing DH, Deme A, et al. Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. Clin Chem 2004; 50:2069-2076. A multigene PCR-assay using four marker genes was described.
7. Benoy IA, Salgado R, Elst H, et al. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res 2005; 7:R210-R219. The association between disseminated tumor cells in bone marrow and vascularization of the primary tumor might be of biological importance.
8. Taubert H, Blümke K, Bilkenroth U, et al. Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. Gyn Oncol 2004; 92:256-261. A correlation between circulating tumor cells and clinical parameters was observed.
9. Ring AE, Zabaglo L, Ormerod MG, et al. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005; 92:906-912. Only little concordance between three molecular markers as well as between ICC and RT-PCR was observed. These findings might reflect distinct populations of cells with different clinical or biological properties.
10. Ferrucci PF, Rabascio C, Mazzetta C, et al. Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. Clin Cancer Res 2004; 10:6039-6046. Mammaglobin positive cells in progenitor cell collections reached prognostic significance for DFS. Such a correlation was not seen when using maspin or CK RT-PCR in the same samples, pointing to biological differences of the various markers in use.
11. Fabisiewicz A, Kulik J, Kober P, et al. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase- polymerase chain reaction assay. Acta Biochim Polonica 2004; 51:747-755.
12. Choesmel V, Pierga J, Nos C, et al. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. Breast Cancer Res 2004; 6:R556-R569. A combination of immunomagnetic cell enrichment, ICC and cytomorphological parameters was applied for the detection of tumor cells in bone marrow.
13. Cerveira N, Torres L, Rocha P, et al. Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. Int J Cancer 2004; 108:592-595.
14. Benoy IH, Elst H, Van der Auwera I, et al. Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer 2004; 91:1813-1820. The authors demonstrated a correlation between ICC and RT-PCR detection of epithelial cells.
15. Bauernhofer T, Zenahlik S, Hofmann G, et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol Rep 2005; 13:179-184. An association of circulating tumor cells with overall survival was observed.
16. Trocciola SM, Hoda S, Osborne MP, et al. Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients? J Am Coll Surg 2005; 200:720-725.
17. Schindlbeck C, Jeschke U, Schulze S, et al. Characterization of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen. Histochem Cell Biol 2005; 123: 631-637.
18. Müller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005; 11:3678-3685. Circulating tumor cells correlated with the occurrence of bone marrow micrometastases and persisted during chemotherapy.
19. Woelfle U, Breit E, Zafrakas K, et al. Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods 2005; 300:136-145.
20. Becker S, Becker-Pergola G, Fehm T, et al. Image analysis systems for the detection of disseminated breast cancer cells on bone-marrow cytospins. J Clin Lab Anal 2005; 19:115-119.
21. Alix-Panabières C, Brouillet J, Fabbro M, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005; 299:177-188.
22. Inoue H, Kajiyama Y, Tsurumaru M. Clinical significance of bone marrow micrometastases in esophageal cancer. Dis Esophagus 2004; 17:328-332. No correlation between disseminated tumor cells and any clinical relevance was observed.
23. Spence GM, Graham ANJ, Mulholland K, et al. Bone marrow micrometastases and markers of angiogenesis in esophageal cancer. Ann Thorac Surg 2004; 78:1944-1950. Micrometastases in bone marrow correlated with tumor stage and tumor vascularity.
24. Koch M, Kienle P, Hinz U, et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 2005; 241:199-205. Tumor cells in the bone marrow and the detection of circulating tumor cells during hepatic resection of colorectal cancer metastases predicted tumor relapse.
25. Frühauf NR, Kasimir-Bauer S, Görlinger K, et al. Peri-operative filtration of disseminated cytokeratin positive cells in patients with colorectal liver metastasis. Langenbecks Arch Surg 2005; 390:15-20. The detection of tumor cells in peripheral blood during hepatic resection of colorectal cancer metastases correlated with disease recurrence.
26. Topal B, Aerts JL, Roskams T, et al. Cancer cell dissemination during curative surgery for colorectal liver metastases. Eur J Surg Oncol 2005; 31:506-511. The detection of circulating tumor cells during hepatic resection of colorectal cancer metastases did not correlate with disease recurrence.
27. O'Connor OJ, Cahill RA, Kirwan WO, Redmond HP. The impact of bone marrow micrometastases on metastatic disease-free survival in patients with colorectal carcinoma. Colorectal Dis 2005; 7:406-409. The presence of micrometastases in bone marrow was not predictive of tumor recurrence.
28. Rolle A, Günzel R, Pachmann U, et al. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC is a predictor for relapse: a preliminary report. World J Surg Oncol 2005; 3:18.
29. Roa JC, de Aretxabala X, Melo A, et al. Detection of bone marrow micrometastases in patients with gallbladder cancer. Rev Med Chil 2004; 132:1489-1498.
30. Bozzi F, Luksch R, Collini P, et al. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood. Diagn Mol Pathol 2004; 13:135-143.
31. Oltra S, Martinez F, Orellana C, et al. The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol 2005; 14:53-57.
32. Oltra S, Martinez F, Orellana C, et al. Minimal residual disease in neuroblastoma: to GAGE or not to GAGA. Oncol Res 2004; 14:291-295.
33. Mocellin S, Del Fiore P, Guarnieri L, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer 2004; 111:741-745.
34. Yang S, Dong J, Li K, et al. Detection of AFP mRNA and melanoma antigen gene-1 mRNA as markers of disseminated hepatocellular carcinoma cells in blood. Hepatobiliary Pancreat Dis Int 2005; 4:227-233. A correlation between circulating tumor cells and clinical parameters was observed, but AFP exhibited only limited specificity for malignant cells.
35. Choesmel V, Anract P, Høifødt H, et al. A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma. Cancer 2004; 101:693-703.
36. Shetye JD, Liljefors ML, Emdin SO, et al. Spectrum of cytokeratin-positive cells in the bone marrow of colorectal carcinoma patients. Anticancer Res 2004; 24:2375-2383. Double immunohistochemical staining of bone marrow clots for p53 and Ki67 along with cytokeratin allowed the sub-classification of cytokeratin-positive cells.
37. Schmidt U, Bilkenroth U, Linne C, et al. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy. Int J Oncol 2004; 24:1393-1399.
38. Schrader M, Weissbach L, Müller M, et al. Detection of germ-cell-tumor-specific gene products in peripheral blood by immunomagnetic tumor cell enrichment followed by RT-PCR. Int J Mol Med 2004; 13:685-690.
39. Reinholz MM, Nibbe A, Jonart LM, et al. Evaluation of a panel of tumor markers for molecular detection of circulating tumor cells in women with suspected breast cancer. Clin Cancer Res 2005; 11:3722-3732. The molecular characterization of circulating tumor cells using mammaglobin and B305D-C offered potential for early detection of invasive breast cancer.
40. Woelfle U, Breit E, Pantel K. Influence of immunomagnetic enrichment on gene expression of tumor cells. J Translat Med 2005; 3:12. Breast cancer cell lines were treated similarly to an immunomagnetic cell separation protocol and differential expression profiling was performed. Comparative cDNA-array analyses of selected and unselected cancer cells indicated no alteration of the gene expression profile.
41. Fehm T, Becker S, Pergola-Becker G, et al. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res 2004; 24:4211-4216. The presence of disseminated tumor cells did not correlate with tumor size and lymph node involvement but was related to p53 expression and progesterone receptor status.
42. Bozionellou V, Mavroudis D, Perraki M, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004; 10:8185-8194.
43. Janku F, Kleibl Z, Novotny J, et al. Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. Neoplasma 2004; 51:204-208.
44. Pierga JY, Bonneton C, Magdelenat H, et al. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 2005; 114:291-298.
45. Conzelmann M, Linnemann U, Berger MR. Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use? Int J Colorectal Dis 2005; 20:137-146.
46. Staritz P, Kienle P, Koch M, et al. Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients. J Exp Clin Cancer Res 2004; 23:633-639. The data suggest a recruitment of circulating tumor cells during chemotherapy in advanced colorectal cancer and these cells were related to overall survival.
47. Wollenberg B, Walz A, Kolbow K, et al. Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN. Onkologie 2004; 27:358-362. A significant correlation between tumor cells in bone marrow and relapse was observed.
48. Klein CA, Blankenstein TJF, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in residual cancer. Lancet 2002; 360:683-689.
49. Woelfle U, Cloos J, Riethdorf L, et al. A new role of cytokeratins as micrometastatis-suppressors in primary breast cancer. Proc Am Assoc Cancer Res 2003; 44:118.
50. Sheehan KM, Cahill RA, McGreal G, et al. Cyclooxygenase-2 expression in primary human colorectal cancer and bone marrow micrometastases. Dig Liver Dis 2004; 36:392-397.
51. Ambros PF, Mehes G, Ambros IM, Ladenstein R. Disseminated tumor cells in the bone marrow: chances and consequences of microscopical detection methods. Cancer Let 2003; 197:29-34.
52. Mehes G, Luegmayr A, Kornmüller R, et al. Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. Am J Path 2003; 163:393-399.
53. Fetsch PA, Cowan KH, Weng DE, et al. Detection of circulating tumor cells and micrometastases in stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry. Diagn Cytopath 2000; 22:323-328.
54. Janni W, Rack B, Lindemann K, Harbeck N. Detection of micrometastatic disease in bone marrow: is it ready for prime time? Oncologist 2005; 10:480-492.
55. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in the BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999; 1:377-388.
56. Swerts K, Ambros PF, Brouzes C, et al. Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. J Histochem Cytochem 2005; DOI: 10.1369/jhc.5C6661.2005. The SIOPEN Neuroblastoma Bone Marrow Committee developed a sensitive and reproducible ICC assay and introduced morphological and immunocytological criteria for the interpretation of results.
57. Ballestrero A, Garuti A, Bertolotto M, et al. Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer. Br J Cancer 2005; 92:1948-1952. The possible interference of cytokines should be taken into account in interpreting results from molecular assays. Mammaglobin is more specific than maspin, as its expression was not inducible.
58. Becker S, Becker-Pergola G, Fehm T, et al. Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR. Clin Chem 2004; 50:785-786. A measurable decrease of CK19 transcripts 2 hours after blood-drawing without differences in terms of storage of samples at room temperature or cooled on ice was observed.
59. Zach O, Wagner H, Kasparu H, et al. Statistical validation of the mammaglobin-nested RT-PCR assay for tumor cell detection in blood of breast cancer patients. BioTechniques 2001; 31:1358-1362.
60. Nuñez-Villar MJ, Martinez-Arribas F, Pollán M, et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 2003; 5:R65-R70.
61. Span PN, Waanders E, Manders P, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol 2004; 22:691-698. The assessment of mammaglobin expression of the tumor might be useful to stratify patients for adjuvant treatment strategies.
62. Zach O, Lutz D. Mammaglobin remains a useful marker for the detection of breast cancer cells in peripheral blood. J Clin Oncol 2005; 23:3160. All breast tumor samples tested were mammaglobin positive when applying nested RT-PCR.
63. Mikhitarian K, Gillanders WE, Almeida JS, et al. An innovative microarray strategy identifies informative molecular markers for the detection of micrometastatic breast cancer. Clin Cancer Res 2005; 11:3697-3704. To evaluate marker genes which are most likely to be informative for the detection of micrometastatic disease, a microarray strategy together with statistical validation was used. In this analysis, mammaglobin and TFF1 turned out to have the highest sensitivity to detect disseminated breast cancer cells.
64. Müller V, Pantel K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res 2004; 6:258-261. In this review, the authors call for an implementation of disseminated tumor cell status in current risk classification systems.
65. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004; 54:295-308.
66. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cell to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 2003; 100:7737-7742.
67. Gangus R, Langer S, Breit E, et al. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 2004; 10:3457-3464. Genomic profiling of single tumor cells may discover novel genes which contribute to distinct biological features such as the ability for metastatic growth and to potential cellular targets for adjuvant and systemic therapies on MRD.
68. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003; 63:5679-5684.